SCHEMBL4725018

SCHEMBL4725018

O=C(Nc1ccc(F)c(Cl)c1)Nc1ncc(-c2cc(C(=O)O)c3cn[nH]c3n2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.44
PDGFRB P09619 3/20 0.44
CNR1 P21554 1/20 0.44
MAOB P27338 1/20 0.43
CSNK1A1 P48729 1/20 0.42
SLC2A1 P11166 1/20 0.42
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
MAPT P10636 5/20 0.41
LMNA P02545 4/20 0.41
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
HTT P42858 3/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
PTPRE P23469 1/20 0.39
CDK8 P49336 1/20 0.39
RPS6KB1 P23443 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724468 0.92 MAPT (0.46) CNR1MAOBMEN1KMT2AMAPT
SCHEMBL4723103 0.90 CNR1 (0.55) KDRCNR1MEN1KMT2AMAPT
SCHEMBL4720666 0.88 BLM (0.44) KDRPDGFRBCNR1MAPTLMNA
SCHEMBL4721455 0.88 MEN1 (0.48) KDRCNR1MEN1KMT2AMAPT
SCHEMBL4724126 0.85 CNR1 (0.47) CNR1MEN1KMT2AMAPTLMNA
SCHEMBL4908646 0.85 NTRK1 (0.41) CNR1MEN1KMT2AMAPTHTT
SCHEMBL4721577 0.84 FLT3 (0.48) KDRCNR1AURKARPS6KB1
SCHEMBL4764052 0.83 GRIK1 (0.43) CNR1MEN1KMT2AMAPTLMNA
SCHEMBL4723548 0.83 ROCK1 (0.42) MEN1KMT2AMAPTSMN1; SMN2NPC1
SCHEMBL4724837 0.82 MEN1 (0.47) MEN1KMT2AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912988-B1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA SA (FR) 2014-04-16 EP claimed
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-31 US claimed
EP-1912988-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF Aventis Pharma S.A. (FR) 2008-04-23 EP claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof PRMT7, PRKACA, PRKX KDR 3171/4885PDGFRB 1529/4885CNR1 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.